{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:28:36Z","timestamp":1792114116641,"version":"4.4.0"},"update-to":[{"DOI":"10.1002\/14651858.cd009043.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2016,6,26]],"date-time":"2016-06-26T00:00:00Z","timestamp":1466899200000}}],"reference-count":64,"publisher":"Wiley","issue":"6","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd009043.pub3","type":"journal-article","created":{"date-parts":[[2016,6,26]],"date-time":"2016-06-26T14:20:34Z","timestamp":1466950834000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":81,"title":["Aripiprazole for autism spectrum disorders (ASD)"],"prefix":"10.1002","volume":"2016","author":[{"given":"Lauren E","family":"Hirsch","sequence":"first","affiliation":[{"name":"University of Calgary; Department of Clinical Neurosciences; Mathison Center, 4th Floor TRW building 3280 Hospital Drive NW Calgary AB Canada T2N 4N1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Pringsheim","sequence":"additional","affiliation":[{"name":"University of Calgary; Department of Clinical Neurosciences, Psychiatry, Pediatrics and Community Health Sciences; Mathison Centre for Mental Health Reseach and Education 4th floor, TRW Building, 4D72, 3280 Hospital Drive NW Calgary AB Canada T2N 4Z6"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,6,26]]},"reference":[{"issue":"1","key":"10.1002\/14651858.CD009043.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4088\/JCP.13m08500","article-title":"Randomized controlled trial investigating the safety and efficacy of aripiprazole in the long-term maintenance treatment of pediatric patients with irritability associated with autistic disorder","volume":"75","author":"Findling","year":"2014","journal-title":"Journal of Clinical Psychiatry"},{"issue":"11","key":"10.1002\/14651858.CD009043.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1097\/CHI.0b013e3181b76658","article-title":"A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder","volume":"48","author":"Marcus","year":"2009","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD009043.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1542\/peds.2008-3782","article-title":"Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder","volume":"124","author":"Owen","year":"2009","journal-title":"Pediatrics"},{"issue":"5","key":"10.1002\/14651858.CD009043.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1089\/cap.2009.0120","article-title":"Line-item analysis of the Aberrant Behaviour Checklist: results from two studies of aripiprazole in the treatment of irritability associated with autistic disorder","volume":"20","author":"Aman","year":"2010","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD009043.pub3-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s11920-010-0172-0","article-title":"Aripiprazole to treat irritability associated with autism: a placebo-controlled, fixed-dose trial","volume":"13","author":"Benton","year":"2011","journal-title":"Current Psychiatry Reports"},{"issue":"4","key":"10.1002\/14651858.CD009043.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2217\/phe.10.45","article-title":"Aripiprazole for irritability associated with autistic disorder in children and adolescents aged 6-17 years","volume":"4","author":"Blankenship","year":"2010","journal-title":"Pediatric Health"},{"key":"10.1002\/14651858.CD009043.pub3-BIB0007|cit7","volume-title":"Low-dose Abilify and the Treatment of Disruptive Behaviours in Children with Autism Spectrum Disorders [PhD thesis]","author":"D'Alessandro","year":"2012"},{"key":"10.1002\/14651858.CD009043.pub3-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"143","DOI":"10.4137\/JCNSD.S4140","article-title":"Aripiprazole: a review of its use in the treatment of irritability associated with autistic disorder patients aged 6-17","volume":"3","author":"Douglas-Hall","year":"2011","journal-title":"Journal of Central Nervous System Disease"},{"issue":"3","key":"10.1002\/14651858.CD009043.pub3-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.nurt.2010.04.001","article-title":"Aripiprazole in autism spectrum disorders and fragile X syndrome","volume":"7","author":"Erickson","year":"2010","journal-title":"Neurotherapeutics"},{"issue":"4","key":"10.1002\/14651858.CD009043.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1517\/14656566.2011.557661","article-title":"Aripiprazole for the treatment of irritability associated with autism","volume":"12","author":"Farmer","year":"2011","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"2","key":"10.1002\/14651858.CD009043.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s10578-013-0390-x","article-title":"A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial","volume":"45","author":"Ghanizadeh","year":"2014","journal-title":"Child Psychiatry and Human Development"},{"issue":"2","key":"10.1002\/14651858.CD009043.pub3-BIB0012|cit12","first-page":"211","article-title":"Aripiprazole improves social interaction in Taiwanese children with pervasive developmental disorder","volume":"33","author":"Huang","year":"2010","journal-title":"Chang Gung Medical Journal"},{"issue":"11 Suppl 3","key":"10.1002\/14651858.CD009043.pub3-BIB0013|cit13","first-page":"A428","article-title":"Efficacy and safety of aripiprazole for the treatment of irritability associated with autistic disorder in children and adolescents (6-17 years): results from two 8-week, randomized, double-blind, placebo controlled trials","volume":"72","author":"Lewis","year":"2009","journal-title":"Neurology"},{"issue":"6","key":"10.1002\/14651858.CD009043.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1089\/cap.2013.0143","article-title":"Aripiprazole decreases irritability in 12 out of 14 youth with autism spectrum disorder","volume":"24","author":"Maloney","year":"2014","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"issue":"6","key":"10.1002\/14651858.CD009043.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"511","DOI":"10.2165\/00023210-200923060-00005","article-title":"Aripiprazole monotherapy in children and young adolescents with pervasive developmental disorders: a retrospective study","volume":"23","author":"Masi","year":"2009","journal-title":"CNS Drugs"},{"key":"10.1002\/14651858.CD009043.pub3-BIB0016|cit16","unstructured":"Narasimhan T Bruce T BallardJF Patkar A Masand P Rech R Poster session III: an open label trial of aripiprazole in the treatment of autism and its correlation to whole blood serotonin levels and serotonin transporter (5HTTPLR) function Neuropsychopharmacology. Proceedings of the American College of Neuropsychopharmacology 45th Annual Meeting; 2006 December 3-7; Hollywood, Florida 2006 S259 60"},{"issue":"1","key":"10.1002\/14651858.CD009043.pub3-BIB0017|cit17","first-page":"e1","article-title":"Safety and tolerability of aripiprazole in the treatment of irritability associated with autistic disorder in pediatric subjects (6-17 years): results from a pooled analysis of 2 studies","volume":"13","author":"Robb","year":"2011","journal-title":"Primary Care Companion for CNS Disorders"},{"issue":"3","key":"10.1002\/14651858.CD009043.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1089\/cap.2004.14.455","article-title":"Aripiprazole for maladaptive behaviour in pervasive developmental disorders","volume":"14","author":"Stigler","year":"2004","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"key":"10.1002\/14651858.CD009043.pub3-BIB0019|cit19","unstructured":"Stigler KA Diener JT Kohn AE Erickson CA Posey DJ. McDougle CJ Poster session II: a prospective open-label study of aripiprazole in youth with Asperger's disorder and pervasive developmental disorder not otherwise specified Neuropsychopharmacology. Proceedings of the American College of Neuropsychopharmacology 45th Annual Meeting; 2006 December 3-7; Hollywood, Florida 2006 S194"},{"issue":"4","key":"10.1002\/14651858.CD009043.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.clinthera.2012.02.023","article-title":"Effect of aripiprazole 2 to 15 mg\/d on health-related quality of life in the treatment of irritability associated with autistic disorder in children: a post hoc analysis of two randomized controlled trials","volume":"34","author":"Varni","year":"2012","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD009043.pub3-BIB0021|cit21","volume-title":"Aberrant Behaviour Checklist: Manual","author":"Aman","year":"1986"},{"issue":"2","key":"10.1002\/14651858.CD009043.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/BF02211843","article-title":"The effects of haloperidol on discrimination learning and behavioural symptoms in autistic children","volume":"19","author":"Anderson","year":"1989","journal-title":"Journal of Autism and Developmental Disorders"},{"key":"10.1002\/14651858.CD009043.pub3-BIB0023|cit23","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2000"},{"key":"10.1002\/14651858.CD009043.pub3-BIB0024|cit24","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013"},{"key":"10.1002\/14651858.CD009043.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"British Journal of Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD009043.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1192\/bjp.bp.108.059345","article-title":"Prevalence of autism spectrum conditions: UK school based population study","volume":"194","author":"Baron-Cohen","year":"2009","journal-title":"British Journal of Psychiatry"},{"issue":"10","key":"10.1002\/14651858.CD009043.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1001\/jamapsychiatry.2013.2053","article-title":"Antipsychotics and the risk of type 2 diabetes mellitus in children and youth","volume":"70","author":"Bobo","year":"2013","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD009043.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/BF01531306","article-title":"The effects of haloperidol on learning and behaviour in autistic children","volume":"12","author":"Campbell","year":"1982","journal-title":"Journal of Autism and Developmental Disorders"},{"issue":"6","key":"10.1002\/14651858.CD009043.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1097\/00004583-199706000-00022","article-title":"Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study","volume":"36","author":"Campbell","year":"1997","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"key":"10.1002\/14651858.CD009043.pub3-BIB0030|cit30","unstructured":"Centers for Disease Control and Prevention Community Report from the Autism and Developmental Disabilities Monitoring (ADDM) Network: a snapshot of autism spectrum disorder among 8-year-old children in multiple communities across the United States in 2010 http:\/\/www.cdc.gov\/ncbddd\/autism\/documents\/community_report_autism.pdf"},{"issue":"16","key":"10.1002\/14651858.CD009043.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1001\/jama.2009.1549","article-title":"Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents","volume":"302","author":"Correll","year":"2009","journal-title":"JAMA"},{"issue":"1","key":"10.1002\/14651858.CD009043.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analysis involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"3","key":"10.1002\/14651858.CD009043.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/aur.239","article-title":"Global prevalence of autism and other pervasive developmental disorders","volume":"5","author":"Elsabbagh","year":"2012","journal-title":"Autism Research"},{"key":"10.1002\/14651858.CD009043.pub3-BIB0034|cit34","unstructured":"Food Drug Administration Label and approval history: ability www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm?fuseraction=Search.Label_ApprovalHistory#apphist"},{"issue":"11","key":"10.1002\/14651858.CD009043.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1176\/appi.ajp.2008.07061035","article-title":"A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia","volume":"165","author":"Findling","year":"2008","journal-title":"American Journal of Psychiatry"},{"issue":"10","key":"10.1002\/14651858.CD009043.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.4088\/JCP.09m05164yel","article-title":"Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study","volume":"70","author":"Findling","year":"2009","journal-title":"Journal of Clinical Psychiatry"},{"issue":"11","key":"10.1002\/14651858.CD009043.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1001\/archpsyc.1989.01810110048007","article-title":"The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability","volume":"46","author":"Goodman","year":"1989","journal-title":"Archives of General Psychiatry"},{"issue":"12","key":"10.1002\/14651858.CD009043.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1517\/14656566.3.12.1773","article-title":"Aripiprazole: profile on efficacy and safety","volume":"3","author":"Goodnick","year":"2002","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1002\/14651858.CD009043.pub3-BIB0039|cit39","volume-title":"Early Clinical Drug Evaluation Unit (ECDEU) Assessment Manual for Psychopharmacology. National Institute Mental Health","author":"Guy","year":"1976"},{"issue":"4","key":"10.1002\/14651858.CD009043.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD009043.pub3-BIB0041|cit41","unstructured":"Higgins JPT Altman DG Sterne J on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from http:\/\/handbook.cochrane.org"},{"key":"10.1002\/14651858.CD009043.pub3-BIB0042|cit42","unstructured":"Higgins JPT Deeks JJ Altman DG on behalf of the Cochrane Statistical Methods Group Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from http:\/\/handbook.cochrane.org"},{"key":"10.1002\/14651858.CD009043.pub3-BIB0043|cit43","unstructured":"Deeks JJ Higgins JPT Altman DG on behalf of the Cochrane Statistical Methods Group Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"1","key":"10.1002\/14651858.CD009043.pub3-BIB0044|cit44","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005040.pub2","article-title":"Risperidone for autism spectrum disorder","author":"Jesner","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD009043.pub3-BIB0045|cit45","first-page":"217","article-title":"Autistic disturbances of affective contact","volume":"2","author":"Kanner","year":"1943","journal-title":"Nervous Child"},{"issue":"5","key":"10.1002\/14651858.CD009043.pub3-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1542\/peds.2009-1522","article-title":"Prevalence of parent-reported diagnosis of autism spectrum disorders among children in the US, 2007","volume":"124","author":"Kogan","year":"2009","journal-title":"Pediatrics"},{"issue":"4","key":"10.1002\/14651858.CD009043.pub3-BIB0047|cit47","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006569.pub3","article-title":"Aripiprazole versus other atypical antipsychotics for schizophrenia","author":"Komossa","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD009043.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s10803-006-0147-5","article-title":"Behavioral and emotional problems in young people with pervasive developmental disorders: relative prevalence, effects of subject characteristics, and empirical classification","volume":"36","author":"Lecavalier","year":"2006","journal-title":"Journal of Autism and Developmental Disorders"},{"issue":"5","key":"10.1002\/14651858.CD009043.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/BF02172145","article-title":"Autism Diagnostic Interview - Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders","volume":"24","author":"Lord","year":"1994","journal-title":"Journal of Autism and Developmental Disorders"},{"issue":"5","key":"10.1002\/14651858.CD009043.pub3-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1542\/peds.2007-2362","article-title":"Management of children with autism spectrum disorders","volume":"120","author":"Myers","year":"2007","journal-title":"Pediatrics"},{"issue":"1","key":"10.1002\/14651858.CD009043.pub3-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1172\/JCI32483","article-title":"Antipsychotics in the treatment of autism","volume":"118","author":"Posey","year":"2008","journal-title":"Journal of Clinical Investigation"},{"key":"10.1002\/14651858.CD009043.pub3-BIB0052|cit52","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"6","key":"10.1002\/14651858.CD009043.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1097\/00004583-199706000-00023","article-title":"Children's Yale-Brown Obsessive Compulsive Scale: reliability and validity","volume":"36","author":"Scahill","year":"1997","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"issue":"8","key":"10.1002\/14651858.CD009043.pub3-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/sj.npp.1300203","article-title":"Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology","volume":"28","author":"Shapiro","year":"2003","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"10.1002\/14651858.CD009043.pub3-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1097\/CHI.0b013e318179964f","article-title":"Psychiatric disorders in children with autism spectrum disorders: prevalence, comorbidity and associated factors in a population derived sample","volume":"47","author":"Simonoff","year":"2008","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"issue":"S212","key":"10.1002\/14651858.CD009043.pub3-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A ratings scale for extrapyramidal side effects","volume":"45","author":"Simpson","year":"1970","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"3","key":"10.1002\/14651858.CD009043.pub3-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1089\/cap.2008.093","article-title":"Aripiprazole in pervasive development disorder not otherwise specified and Asperger's disorder: a 14-week, prospective, open-label study","volume":"19","author":"Stigler","year":"2009","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD009043.pub3-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/00005650-199902000-00003","article-title":"The PedsQL: measurement model for the pediatric quality of life inventory","volume":"37","author":"Varni","year":"1999","journal-title":"Medical Care"},{"issue":"2","key":"10.1002\/14651858.CD009043.pub3-BIB0059|cit59","first-page":"279","article-title":"Critical analysis of the disability in Parkinson's disease","volume":"5","author":"Webster","year":"1968","journal-title":"Modern Treatment"},{"key":"10.1002\/14651858.CD009043.pub3-BIB0060|cit60","volume-title":"International Statistical Classification of Diseases and Related Health Problems, 10th Revision","volume":"1-3","author":"World Health Organization","year":"1994"},{"issue":"1","key":"10.1002\/14651858.CD009043.pub3-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1136\/adc.2004.062083","article-title":"Systematic review of prevalence studies of autism spectrum disorders","volume":"91","author":"Williams","year":"2006","journal-title":"Archives of Diseases in Childhood"},{"issue":"1","key":"10.1002\/14651858.CD009043.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1176\/ajp.143.1.35","article-title":"The Overt Aggression Scale for the objective rating of verbal and physical aggression","volume":"143","author":"Yudofsky","year":"1986","journal-title":"American Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD009043.pub3-BIB0063|cit63","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009043","article-title":"Aripiprazole for Autism Spectrum Disorders (ASD)","author":"Ching","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD009043.pub3-BIB0064|cit64","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009043.pub2","article-title":"Aripiprazole for autism spectrum disorders (ASD)","author":"Ching","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD009043.pub3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T03:55:22Z","timestamp":1718337322000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD009043.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Developmental, Psychosocial and Learning Problems Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,6,26]]},"references-count":64,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2016,6]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd009043.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,26]]}}}